JP 2060 is a multi-phase project that involves the identification and development of capabilities required to prevent, treat, manage and evacuate casualties in joint operations in the defence of Australia and its interests.

JP 2060 Phase 3 Deployable Health Capability will acquire modernised health materiel for Army and Air Force, and materiel systems for the Deployable Health Capability to enable best practice military medicine. The capability provides health modules and services to enable health care delivery and will address the joint trauma system, force health protection, casualty evacuation and health materiel and logistics components of the Deployable Operational Health System.

The RFT for JP 2060 is expected to be released in the second quarter of 2017.

Leidos Australia said it recognises the value that Australian industry can play in developing and delivering a compliant and competitive solution for the Commonwealth, and as such would like to maximise the opportunities available for competitive Australian industry to be considered for participation in Leidos Australia’s tender response.

The primary capabilities that Leidos Australia are seeking from Australian industry for JP 2060 Phase 3 include:

• transportation solutions;

• physical structures and associated infrastructure;
• medical equipment;
• dental equipment;
• warehousing support; and
• logistics support.

Leidos said if there are any Australian companies, particularly small to medium enterprises, interested in being part of this exciting opportunity as a potential supplier for Leidos Australia, they can register their interest here and a member of Leidos Australia’s sourcing and commercial management team will get in contact with them.